Evidence map›Paper›PMID 25378595›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2014

CD4 T cells specific for a latency-associated γ-herpesvirus epitope are polyfunctional and cytotoxic.

Michael L Freeman, Claire E Burkum, Tres Cookenham, Alan D Roberts, Kathleen G Lanzer, Gail E Huston, Meghan K Jensen, John Sidney, Bjoern Peters, Jacob E Kohlmeier and 4 more

Open access · greenAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Glutaminolysis of CD4Journal of inflammation research · 2024
    Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Michael L FreemanTrudeau Institute, Saranac Lake, NY 12983;
Claire E BurkumTrudeau Institute, Saranac Lake, NY 12983;
Tres CookenhamTrudeau Institute, Saranac Lake, NY 12983;
Alan D RobertsTrudeau Institute, Saranac Lake, NY 12983;
Kathleen G LanzerTrudeau Institute, Saranac Lake, NY 12983;
Gail E HustonTrudeau Institute, Saranac Lake, NY 12983;
Meghan K JensenTrudeau Institute, Saranac Lake, NY 12983;
John SidneyDivision of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037;
Bjoern PetersDivision of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037;
Jacob E KohlmeierTrudeau Institute, Saranac Lake, NY 12983;
David L WoodlandTrudeau Institute, Saranac Lake, NY 12983;
Linda F van DykDepartment of Microbiology, University of Colorado School of Medicine, Aurora, CO 80045; and Department of Immunology, University of Colorado School of Medicine, Aurora, CO 80045.
Alessandro SetteDivision of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037;
Marcia A BlackmanTrudeau Institute, Saranac Lake, NY 12983; mblackman@trudeauinstitute.org.
Trudeau Institute · USLa Jolla Institute for Immunology · USUniversity of Colorado Denver · US

Funding

University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0M
T CELL IMMUNITY TO MHV 68, A MURINE GAMMA HERPEVIRUSR01AI042927 · NIAID · TRUDEAU INSTITUTE, INC. · PI BLACKMAN, MARCIA A · 1998 to 2008
$2.5M
Research Training in Immunology and Infectious DiseasesT32AI049823 · NIAID · TRUDEAU INSTITUTE, INC. · PI COOPER, ANDREA M · 2001 to 2015
$2.1M
Cyclin requirements in gammaherpesvirus infection and diseaseR01CA168558 · NCI · UNIVERSITY OF COLORADO DENVER · PI VAN DYK, LINDA F. · 2012 to 2016
$1.5M
Immunogenicity and efficacy of genetically engineered gamma-herpesvirus vaccinesRC2CA148250 · NCI · TRUDEAU INSTITUTE, INC. · PI BLACKMAN, MARCIA A, SUN, REN · 2009 to 2010
$1000k
Can persistent gamma-herpesviruses be purged from the host?R21AI082919 · NIAID · TRUDEAU INSTITUTE, INC. · PI BLACKMAN, MARCIA A · 2009 to 2010
$502k
CD* T cell responses to gamma-herpesviral infectionF32AI084327 · NIAID · TRUDEAU INSTITUTE, INC. · PI FREEMAN, MICHAEL L · 2009 to 2010
$98k
NCI NIH HHS CA148250NCI NIH HHS CA168558NCI NIH HHS P30 CA046934NCI NIH HHS R01 CA168558NCI NIH HHS RC2 CA148250NIAID NIH HHS AI082919NIAID NIH HHS AI42927NIAID NIH HHS F32 AI084327NIAID NIH HHS F32AI084327NIAID NIH HHS HHSN272200900042CNIAID NIH HHS HHSN272200900044CNIAID NIH HHS HHSN272201300006CNIAID NIH HHS R01 AI042927NIAID NIH HHS R21 AI082919NIAID NIH HHS T32 AI049823NIAID NIH HHS T32AI049823
6 · The paper itself

Abstract

The oncogenic γ-herpesviruses EBV and Kaposi sarcoma-associated herpesvirus are ubiquitous human pathogens that establish lifelong latent infections maintained by intermittent viral reactivation and reinfection. Effector CD4 T cells are critical for control of viral latency and in immune therapies for virus-associated tumors. In this study, we exploited γHV68 infection of mice to enhance our understanding of the CD4 T cell response during γ-herpesvirus infection. Using a consensus prediction approach, we identified 16 new CD4 epitope-specific responses that arise during lytic infection. An additional epitope encoded by the M2 protein induced uniquely latency-associated CD4 T cells, which were not detected at the peak of lytic infection but only during latency and were not induced postinfection with a latency-deficient virus. M2-specific CD4 T cells were selectively cytotoxic, produced multiple antiviral cytokines, and sustained IL-2 production. Identification of latency-associated cytolytic CD4 T cells will aid in dissecting mechanisms of CD4 immune control of γ-herpesvirus latency and the development of therapeutic approaches to control viral reactivation and pathology.

Indexed as

Cytotoxicity, ImmunologicVirus LatencyAmino Acid SequenceAnimalsCD4-Positive T-LymphocytesCytokinesEpitopes, T-LymphocyteGammaherpesvirinaeHerpesviridae InfectionsInterferon-gammaLymphocyte ActivationMiceMolecular Sequence DataPeptidesT-Cell Antigen Receptor SpecificityCytokinesEpitopes, T-LymphocyteInterferon-gammaPeptides

Identifiers

PMID25378595
PMCPMC4301266
OpenAlexW1826250772

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.